← Leaderboards
Andras Perl
Upstate Medical University
$17,954,100
Attributed
$22,877,580
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2008–25$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,877,580 · 11
By mechanism
R01$14,607,360 · 6
U01$7,081,470 · 1
R34$648,000 · 2
R56$274,750 · 1
R21$266,000 · 1
Top collaborators
- Michael P Mcdermott7 shared
- Daniel J. Wallace5 shared
Others in their field
Top investigators on “Systemic Lupus Erythematosus”
- Ignacio E. Sanz · University Of Rochester$57,737,718
- George C Tsokos · Beth Israel Deaconess Medical Center$37,219,358
- David Wofsy · University Of California, San Francisco$36,472,228
- Betty Diamond · Feinstein Institute For Medical Research$32,406,714
- John Barker Harley · Cincinnati Va Medical Center Research$30,355,689
- Patrick M Gaffney · University Of Minnesota Twin Cities$27,964,103
Research focus
Systemic Lupus ErythematosusProductionT-LymphocyteLupusInflammatoryAutoimmunityProteinsComplexBaseSirolimusMitochondriaPathogenesisInflammationMediatingCellsT-Cell ActivationIn VivoEtiologyLupus Prone MiceFunctional DisorderMetabolicOxidative StressAutoantibodiesReactive Oxygen Intermediate
Grant awards (52)
SLE Treatment with N-acetylcysteine$1,310,215
U01 · FY2025 · AR · contact PI
SLE Treatment with N-acetylcysteine$1,437,594
U01 · FY2024 · AR · contact PI
Metabolic Control of Systemic Autoimmunity$486,000
R01 · FY2024 · AI · contact PI
SLE Treatment with N-acetylcysteine$1,447,294
U01 · FY2023 · AR · contact PI
Metabolic Control of Systemic Autoimmunity$486,000
R01 · FY2023 · AI · contact PI
Metabolic Control of Systemic Autoimmunity$486,000
R01 · FY2022 · AI · contact PI
SLE Treatment with N-acetylcysteine$1,386,367
U01 · FY2021 · AR · contact PI
Metabolic Control of Systemic Autoimmunity$486,000
R01 · FY2021 · AI · contact PI
SLE Treatment with N-acetylcysteine$1,500,000
U01 · FY2020 · AR · contact PI
Metabolic Control of Systemic Autoimmunity$486,000
R01 · FY2020 · AI · contact PI
Endocytic Control of Autophagosome Formation in Lupus T cells$405,000
R01 · FY2020 · AI · contact PI
Endocytic Control of Autophagosome Formation in Lupus T cells$405,000
R01 · FY2019 · AI · contact PI
Metabolic Control of T-cell Lineage Specification in SLE$405,000
R01 · FY2019 · AI · contact PI
Treatment of SLE with sirolimus$243,000
R34 · FY2019 · AI · contact PI
Metabolic Control of T-cell Lineage Specification in SLE$405,000
R01 · FY2018 · AI · contact PI
Endocytic Control of Autophagosome Formation in Lupus T cells$405,000
R01 · FY2018 · AI · contact PI
Endocytic Control of Autophagosome Formation in Lupus T cells$405,000
R01 · FY2017 · AI · contact PI
Metabolic Control of T-cell Lineage Specification in SLE$405,000
R01 · FY2017 · AI · contact PI
Treatment of Systemic Lupus Erythematosus (SLE) with N-acetylcysteine (NAC)$202,500
R34 · FY2017 · AR · contact PI
Metabolic Control of T-cell Lineage Specification in SLE$403,958
R01 · FY2016 · AI · contact PI
Endocytic Control of Autophagosome Formation in Lupus T cells$403,750
R01 · FY2016 · AI · contact PI
Treatment of Systemic Lupus Erythematosus (SLE) with N-acetylcysteine (NAC)$202,500
R34 · FY2016 · AR · contact PI
Metabolic Control of T-cell Lineage Specification in SLE$402,500
R01 · FY2015 · AI · contact PI
Pathogenesis and Treatment of Liver Disease in Transaldolase Deficiency$316,185
R01 · FY2013 · DK · contact PI
Genetic and Immunological Impact of the HRES-1/Rab4 Locus in SLE$289,287
R01 · FY2013 · AI · contact PI
Pathogenesis and Treatment of Liver Disease in Transaldolase Deficiency$327,653
R01 · FY2012 · DK · contact PI
Genetic and Immunological Impact of the HRES-1/Rab4 Locus in SLE$307,751
R01 · FY2012 · AI · contact PI
Metabolic control of systemic autoimmunity$307,751
R01 · FY2012 · AI · contact PI
Treatment of SLE with N-acetylcysteine$384,689
R01 · FY2011 · AT · contact PI
Pathogenesis and Treatment of Liver Disease in Transaldolase Deficiency$327,653
R01 · FY2011 · DK · contact PI
Genetic and Immunological Impact of the HRES-1/Rab4 Locus in SLE$307,751
R01 · FY2011 · AI · contact PI
Metabolic control of systemic autoimmunity$307,751
R01 · FY2011 · AI · contact PI
Pathogenesis and Treatment of Liver Disease in Transaldolase Deficiency$395,000
R01 · FY2010 · DK · contact PI
Treatment of SLE with N-acetylcysteine$388,575
R01 · FY2010 · AT · contact PI
Genetic and Immunological Impact of the HRES-1/Rab4 Locus in SLE$310,860
R01 · FY2010 · AI · contact PI
Metabolic control of systemic autoimmunity$310,860
R01 · FY2010 · AI · contact PI
Metabolic control of systemic autoimmunity$448,833
R01 · FY2009 · AI · contact PI
Treatment of SLE with N-acetylcysteine$392,500
R01 · FY2009 · AT · contact PI
Genetic and Immunological Impact of the HRES-1/Rab4 Locus in SLE$314,000
R01 · FY2009 · AI · contact PI
Treatment of SLE with N-acetylcysteine$392,500
R01 · FY2008 · AT · contact PI
Metabolic control of systemic autoimmunity$274,750
R01 · FY2008 · AI · contact PI
Genetic and Immunological Impact of the HRES-1/Rab4 Locus in SLE$274,750
R56 · FY2008 · AI · contact PI
Mitochondrial dysfunction in patients with SLE$266,000
R21 · FY2004 · AI
IMPACT OF HRES-1 ENDOGENOUS RETROVIRUS IN SLE$226,950
R01 · FY2004 · AI
MOLECULAR BIOLOGY OF TRANSALDOLASE$226,100
R01 · FY2004 · DK
IMPACT OF HRES-1 ENDOGENOUS RETROVIRUS IN SLE$226,950
R01 · FY2003 · AI
MOLECULAR BIOLOGY OF TRANSALDOLASE$226,100
R01 · FY2003 · DK
MOLECULAR BIOLOGY OF TRANSALDOLASE$226,100
R01 · FY2002 · DK
IMPACT OF HRES-1 ENDOGENOUS RETROVIRUS IN SLE$215,603
R01 · FY2002 · AI
IMPACT OF HRES-1 ENDOGENOUS RETROVIRUS IN SLE$226,950
R01 · FY2001 · AI
MOLECULAR BIOLOGY OF TRANSALDOLASE$226,100
R01 · FY2001 · DK
IMPACT OF HRES-1 ENDOGENOUS RETROVIRUS IN SLE$226,950
R01 · FY2000 · AI